GHRH Analog · FDA-Approved · Protocol Guide
Tesamorelin: The Complete Guide You Have Been Looking For
No marketing hype. No protocol myths. What the clinical evidence actually says about the only GHRH analog with Phase III data and an FDA approval.
- FDA Status
- FDA-Approved (Egrifta, 2010)
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- Rx Peps Direct, clinician-supervised
- Access
- 28 States + DC
Our promise: This guide tells you what tesamorelin cannot do as clearly as what it can. We include non-response rates, reversibility data, and side effect frequencies that other sources skip. If a claim is not backed by clinical evidence, we say so.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed September 29, 2026.On this page
Section 01
What Tesamorelin Actually Is
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland and triggers the natural, pulsatile release of growth hormone. It does not inject GH directly. That matters because pulsatile release preserves your body's feedback mechanisms, unlike exogenous HGH which bypasses them entirely.
Tesamorelin was FDA-approved in November 2010 under the brand name Egrifta (NDA 22-505) for one specific indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That Phase III clinical program produced some of the most robust visceral fat reduction data available for any peptide, including a 15 to 18 percent reduction in visceral adipose tissue (VAT) after 26 weeks at 2 mg per day.
15 to 18%
Visceral fat reduction at 26 weeks in Phase III trials
44
Amino acids in the tesamorelin molecule
2010
FDA approval year. 15+ years of human safety data
Section 02
Who It Is Actually For
Off-label, tesamorelin is used across four consumer profiles with meaningfully different goals. Understanding which profile fits you determines whether tesamorelin is the right choice, and what realistic success looks like for you.
| Profile | Primary Goal | Fit |
|---|---|---|
| Metabolic Optimizer (Male, 35 to 55, often on TRT) | Visceral fat reduction, body recomposition, IGF-1 optimization | Excellent |
| Anti-Aging Biohacker (Mixed gender, 45 to 65) | Longevity protocol, skin quality, sleep improvement, injury recovery | Strong |
| Performance Athlete (Male, 25 to 40, bodybuilding focus) | Fat loss during cut, lean mass preservation | Moderate |
| Aesthetic-Only Goals (Primary goal is visible belly fat) | External subcutaneous fat reduction | Poor Fit |
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
For Women
Tesamorelin for Women
Women can take tesamorelin, but most of the research was done in men. In the two pivotal Egrifta trials, which cut deep belly (visceral) fat by about 15 percent over 26 weeks, roughly 14 to 16 percent of participants were women (Falutz et al., 2010). The most useful trial for women outside HIV gave tesamorelin for 12 months to 60 adults with abdominal obesity, 21 of them women. Visceral fat fell compared with placebo, and the researchers found no difference in effect by sex (Makimura et al., 2012).
| Question | For women |
|---|---|
| Can women take it? | Yes, after a provider review. The approved use is belly fat in adults with HIV-related lipodystrophy; other use is off-label. |
| Dosage for women | The same protocol as for men. There is no separate women's dose in the trials, and your provider sets yours. |
| Before and after | Expect a smaller waist rather than a lower scale weight. Trials measured deep belly fat on scans; fat under the skin changed little. |
| Pregnancy | Contraindicated. The label says it offers no benefit in pregnancy and could harm a fetus. Stop it if you are pregnant or trying to conceive. |
Question
For women
Question
For women
Question
For women
Question
For women
Section 03
How It Works
Tesamorelin binds to GHRH receptors in the anterior pituitary gland and stimulates the natural, pulsatile release of growth hormone. GH then triggers the liver to produce insulin-like growth factor-1 (IGF-1), which drives the downstream metabolic effects, most notably lipolysis (fat breakdown) in visceral adipose tissue.
The mechanism differs critically from exogenous HGH. Because tesamorelin stimulates your own pituitary to release GH naturally, the release remains pulsatile and feedback-regulated. Your body's somatostatin system still applies the brakes. That is why tesamorelin's side effect profile is significantly more favorable than synthetic HGH, and why IGF-1 levels typically stay within physiological ranges rather than spiking to supraphysiological levels.
Section 04
Realistic Expectations, Honestly
This is the section most guides skip. The community's biggest frustration with tesamorelin is calibration failure: expecting results in 4 weeks when the molecule requires 3 to 6 months. We are going to set the record straight.
The Timeline That Actually Matches Clinical Data
Early Adaptation
Some users notice improved sleep quality and mild water retention. No measurable fat changes. Any vendor claiming visible results in 1 to 2 weeks is overstating the evidence.
Early Adaptation
In clinical trials, IGF-1 levels are rising measurably by now, but there is little you can see or feel yet. Subcutaneous appearance is unlikely to change yet. Do not assess effectiveness at this stage.
Metabolic Shift
Some users begin noticing waistline changes, particularly those with significant baseline visceral fat. In trials, triglycerides and liver enzymes also improved. Skin quality improvements frequently reported at this stage.
Minimum Assessment Point
First meaningful assessment of effectiveness. Clinical trials show measurable VAT reduction appearing between 8 and 16 weeks. If no measurable or subjective change by week 12, discuss with your Rx Peps Direct clinician before continuing.
Full Clinical Effect
Phase III data shows peak VAT reduction at 26 weeks. The 15 to 18 percent visceral fat reduction number comes from this timepoint. This is the minimum timeframe to fully evaluate your response.
Section 05
Dosing Protocol
The FDA-approved dose is 2 mg subcutaneously once daily. The dose is not weight-based. The Phase III trials used a fixed dose across the entire participant population. Multiple sources in the community suggest weight-adjusted dosing calculators, but these have no clinical basis.
| Context | Dose | Timing | Evidence Basis |
|---|---|---|---|
| FDA-Approved Protocol | 2 mg per day | Once daily, any time | Phase III RCT |
| Rx Peps Direct Protocol, step 1 | 0.6 mg per day (20 units, 3 mg/mL vial) | Mon-Fri, evening, weeks 6 to 10 | Clinic Protocol |
| Rx Peps Direct Protocol, step 2 | 1.04 mg per day (13 units, 8 mg/mL vial) | Mon-Fri, evening preferred | Clinic Protocol |
| Rx Peps Direct Protocol, step 3 (maximum) | 1.5 mg per day (50 units, 3 mg/mL vial) | Mon-Fri, evening, weeks 11 to 26 | Clinic Protocol |
| Telehealth Reduced-Dose (common in some clinics) | 0.5 to 1 mg per day | Varies | Community Derived |
| Weight-Based Calculators | Variable formulas | Various | No Clinical Basis |
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Titration Start (Rx Peps Direct Standard)
Draw to the 20-unit mark on a U-100 insulin syringe
20 units = 0.2 mL = 0.6 mg
Daily subcutaneous injection into abdominal fat. Used for weeks 1 to 4 before your clinician assesses response and considers dose escalation.
FDA-Approved Full Dose
Volume varies by vial concentration
2 mg per day
The Phase III protocol dose, and the dose behind the visceral-fat figures on this page. Rx Peps Direct does not prescribe to this level: the titration tops out at 1.5 mg on the maintenance step, which is 75 percent of it.
Injection Site Guidance
Inject subcutaneously into abdominal fat. Rotate injection sites within the abdomen to avoid scar tissue buildup. Avoid the 2-inch zone around the navel. Standard insulin syringes (28 to 31 gauge, 6 to 8 mm needle length) work well. Allow the vial to reach room temperature before injecting to reduce discomfort.
Section 06
Cycling: What the Evidence Says
The cycling debate is one of the most contentious, misinformation-heavy topics in the tesamorelin community. Here is what is actually known versus community mythology.
| Claim | Source | Evidence Level |
|---|---|---|
| Must cycle to prevent GH desensitization | Forum extrapolation | Theoretical |
| Continuous use up to 52 weeks is documented | Phase III safety extension | Phase III Data |
| 5-on / 2-off is sufficient cycling | Community consensus | No Direct Evidence |
| Visceral fat reaccumulates within 12 weeks of stopping | Phase III follow-up | Documented |
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Side Effects and How to Manage Them
Tesamorelin has the most thoroughly characterized side effect profile of any peptide Rx Peps Direct prescribes: 15 years of Phase III and post-approval data from the Egrifta program. The side effects below are drawn from the Phase III trials (n=543 in LIPO-010A and LIPO-010B) and the 52-week safety extension study, not from community inference.
| Side Effect | Frequency | When | Mitigation |
|---|---|---|---|
| Injection site reaction (redness, swelling, pruritus) | Common (25-30%) | First 4 to 8 weeks | Rotate sites between abdomen, thigh, and upper arm. OBP ships pre-reconstituted: no reconstitution variability. Typically diminishes by week 8. |
| Peripheral edema (fluid retention, ankles or hands) | Common (15-20%) | First 4 to 8 weeks | Moderate sodium restriction and leg elevation when sedentary. Resolves on discontinuation if needed. Do not add diuretics without provider approval. |
| Arthralgia (joint pain, commonly hands and wrists) | Common (12-18%) | Weeks 2 to 12 | Distributed across small joints. Dose reduction to 0.8 mg typically resolves. Resolves on discontinuation in most patients. |
| Glucose elevation (IGF-1-mediated insulin resistance) | Common (10-15%) | Ongoing | Report rising home glucose readings, increased thirst, or frequent urination. Diabetic and pre-diabetic patients should coordinate glucose monitoring with the doctor who manages their diabetes. |
| Carpal tunnel symptoms (paresthesia, hand weakness) | Uncommon (8-10%) | Weeks 4 to 12 | Dose-dependent. Reduce to 0.8 mg if symptoms appear. Resolves on discontinuation in most cases. |
| Nausea | Uncommon (5-8%) | First 2 to 4 weeks | Evening injection minimizes daytime nausea. Self-limiting in most patients. |
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Side Effect
Frequency
When
Mitigation
Section 07
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), clinician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Storage
Refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Never freeze a reconstituted vial. Use within the Beyond Use Date printed on the label, per USP <797> sterile compounding standards.
Section 08
Tracking Your Response
Your protocol is guided by what you and your clinician can observe over time: waist measurements, how you feel, and side effects.
Weekly Self-Monitoring Protocol
These checkpoints give you and your clinician a running picture of how your body is responding. Tesamorelin's FDA-approved status means the expected response curve is well established: deviations are meaningful.
| Metric | Frequency | Tool | Signal to Report |
|---|---|---|---|
| Waist circumference | Bi-weekly, same time and tape placement | Measuring tape | No reduction at week 12: clinician review of response and protocol adherence |
| Fasting blood glucose (if pre-diabetic or at risk) | Weekly in first 8 weeks, then monthly | Home glucometer | Fasting glucose consistently >100 mg/dL: report; IGF-1-mediated insulin resistance may require dose adjustment |
| Joint pain and swelling (hands, wrists, ankles) | Weekly (0-10 severity) | Phone note | Worsening beyond week 8 or new joints involved: discuss dose reduction with provider |
| Injection site appearance | Each injection | Visual inspection | Redness expanding beyond 2 cm, warmth, or nodule: contact provider |
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Metric
Frequency
Tool
Signal to Report
Section 09
Stacking
Tesamorelin pairs well with non-GH-axis compounds and with TRT for men over 45. Stacking with other GH-axis compounds (HGH, MK-677) increases unpredictability without proportional benefit.
Pairs Well With
Ipamorelin
Different receptor (ghrelin) means complementary, not redundant, GH stimulation. Available as combo (Tesamorelin / Ipamorelin).
BPC-157
Tissue repair and gut healing. Complementary mechanism, no known interaction.
Optimized TRT
Tesamorelin layered onto established testosterone therapy is one of the highest-fit applications for men 45 plus targeting visceral fat.
MOTS-c
Mitochondrial peptide. Targets metabolic function via a different pathway.
Approach With Caution
Exogenous HGH
Combining GH secretagogue with exogenous GH causes supraphysiologic GH levels. Clinician assessment required.
MK-677 (Ibutamoren)
Oral GH secretagogue. Can cause sustained GH elevation and insulin resistance when stacked.
Glucocorticoids
Suppress GH response. May blunt the IGF-1 signal of tesamorelin.
AOD-9604
Targets visceral and subcutaneous fat with a different mechanism. Overlap with tesamorelin produces unclear stacking benefit.
Section 10
Pricing
| Option | Medication Cost | Medical Cost | Notes |
|---|---|---|---|
| Brand-Name Egrifta (specialty pharmacy) | $3,000 to $6,000 per month range | Insurance and prescriber dependent | Branded finished form for HIV-associated lipodystrophy. Out-of-pocket cost without insurance is prohibitive for most off-label users. |
| Other Online Clinics | $300 to $500 per month | Visit fees often bundled and not disclosed publicly | Per-cycle pricing varies. Verify all-in cost before committing. |
| Optimal Balance Pharmacy + Rx Peps Direct | $100 per 15 mg vial, paid to pharmacy | $39 visit fee, paid to Rx Peps Direct | Pre-reconstituted, FedEx overnight. |
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Who You Pay, and What For
Pharmacy: Medication
$100 per 15 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted, FedEx overnight in a reusable cooled travel case.
Medical Service: Clinician Consultation
$39 medical visit fee. Intake consultation, protocol design, prescription writing, and follow-up check-ins. Billed by Rx Peps Direct for the medical service only.
Section 11
Legal Access in 29 States
FDA-Approved Finished Form
Egrifta, branded by Theratechnologies
Compounded, Not an Approved Product
The compounded vial is not Egrifta and is not FDA approved
Off-Label Use of an Approved Molecule
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy; this compounded vial is a different product
Regulated as a Biological Product
Egrifta moved from NDA to BLA 022505 on 3/23/2020 under the BPCI Act
Tesamorelin has an FDA-approved finished form, Egrifta, for HIV-associated lipodystrophy. Its regulatory status changed on March 23, 2020: under the BPCI Act transition, tesamorelin is a 44-amino-acid polypeptide, above the 40-amino-acid line the FDA uses to separate drugs from biological products, so Egrifta was deemed a licensed biological product (BLA 022505) rather than an approved drug. That distinction matters for how a compounded preparation is treated, and it is a question to raise with your prescriber and the dispensing pharmacy.
Off-label prescribing is a standard, legal practice in U.S. medicine. Your prescriber will explain the regulatory status and evidence base for your specific protocol during your consultation.
Section 12
Community Q&A
Will tesamorelin shrink the belly fat I can see in the mirror?
Tesamorelin reduces visceral fat, the deep abdominal fat around your organs, not subcutaneous fat, the fat you can pinch. The visible mirror change is often subtle even when the metabolic benefit is significant. If your goal is purely aesthetic, you may not see a dramatic change.
How long until I see results?
Phase III clinical data shows measurable visceral fat reduction between weeks 8 and 16, with peak effect at 26 weeks. Minimum useful protocol is 12 weeks. Full evaluation requires 26 weeks of consistent daily injection.
What happens when I stop?
Clinical data confirms visceral fat reaccumulates within approximately 12 weeks of discontinuation. Tesamorelin is a maintenance therapy. Plan accordingly.
Is tesamorelin safe long-term?
The Egrifta program documented continuous use up to 52 weeks without loss of effect or new safety signals. Raised blood sugar is the most commonly reported safety finding, which is why your Rx Peps Direct clinician asks about blood sugar symptoms at check-ins. If you have diabetes or pre-diabetes, keep your own doctor involved.
What if I am not responding?
If nothing has changed by week 12, your clinician will review dosing, adherence, sleep, and your health history. Roughly 31 percent of Phase III participants did not achieve the primary endpoint. Some patients are non-responders despite confirmed adherence.
Can I use tesamorelin with TRT?
Yes. Tesamorelin layered onto established testosterone therapy is one of the highest-fit clinical applications for men 45 plus targeting visceral fat. Your Rx Peps Direct clinician will review your existing TRT protocol at intake.
What happens if Optimal Balance Pharmacy is out of stock?
Pharmacy supply chains can fluctuate. If Optimal Balance is temporarily unable to fill your prescription, your Rx Peps Direct clinician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 13
The Rx Peps Direct Model
Tesamorelin is the only GHRH analog with Phase III trial data and an FDA approval. The Egrifta program established its safety profile across 52 weeks of continuous use. Within those limits, the visible mirror change is subtle, the non-responder rate is roughly 31 percent, and visceral fat reaccumulates when you stop. Rx Peps Direct clinicians will set realistic expectations based on your health history and goals.
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your tesamorelin under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight. The pharmacy ships the medication directly to you and bills you for the medication.
Medical Service: Rx Peps Direct Clinicians
A licensed clinician reviews your history, designs your protocol, writes your prescription, and checks your response at follow-up. Rx Peps Direct bills the $39 medical visit fee for this service.
Transparent Safety Communication
The guide above flags the 31 percent non-responder rate, the subcutaneous vs visceral fat distinction, the reaccumulation timeline, and the biological-product status of the molecule. We do not hide limitations to make a sale.
Legal Access in 29 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a prescription. Tesamorelin has an FDA-approved finished form, Egrifta, which the FDA has regulated as a licensed biological product since March 2020.
References
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010. PMID: 20101189
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010. PMID: 20554713
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PMID: 25038357
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. PMID: 21668043
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed Rx Peps Direct prescriber.
GHRH analog (GRF 1-29)
Sermorelin protocol guide: pharmacology, dosing, tracking your response, and the non-responder reality
The only GHRH analog still Category 1 compoundable. Daily injection, 6 to 12 month protocol, 30 to 40 percent non-responder rate, and IGF-1 the biomarker that decides the answer.
Growth hormone stack
CJC-1295 / Ipamorelin protocol guide: dosing, units-to-mcg, timelines, and the legal pathway
Pulsatility, DAC vs no-DAC, syringe math, the 90-day rule, gray-market purity data, and the 503A pathway. Written for the patient who wants the full picture.
Oral GH secretagogue (MK-677)
Ibutamoren (MK-677) guide: oral ghrelin receptor agonist, water retention, glucose elevation, WADA prohibition
The only oral GH secretagogue. Real GH and IGF-1 elevation. Real water retention. Real fasting-glucose drift. WADA prohibited. Monitoring is mandatory.
Continue reading